question_id,date,category,question_text,baseline_success,baseline_actually_answered,baseline_has_expected,baseline_confidence,baseline_text,baseline_error,baseline_time,baseline_input_tokens,baseline_output_tokens,togomcp_success,togomcp_has_expected,togomcp_confidence,togomcp_text,togomcp_error,togomcp_time,togomcp_input_tokens,togomcp_output_tokens,togomcp_cache_creation_input_tokens,togomcp_cache_read_input_tokens,tools_used,tool_details,value_add,expected_answer,notes
73,2026-01-31,Structured Query,Find enzymes that catalyze oxidoreductase reactions using NAD+ as cofactor.,True,True,True,0.5555555555555556,"I can help you identify enzymes that catalyze oxidoreductase reactions using NAD+ as a cofactor.

## Major Classes of NAD+-Dependent Oxidoreductases:

### 1. **Dehydrogenases**
These are the most common NAD+-dependent enzymes:

- **Alcohol dehydrogenase** (EC 1.1.1.1) - oxidizes alcohols to aldehydes/ketones
- **Lactate dehydrogenase** (EC 1.1.1.27) - converts lactate to pyruvate
- **Malate dehydrogenase** (EC 1.1.1.37) - oxidizes malate to oxaloacetate
- **Glyceraldehyde-3-phosphate dehydrogenase** (EC 1.2.1.12) - key glycolytic enzyme
- **Isocitrate dehydrogenase** (EC 1.1.1.41) - in citric acid cycle
- **α-Ketoglutarate dehydrogenase** (EC 1.2.4.2) - in citric acid cycle
- **Glutamate dehydrogenase** (EC 1.4.1.2-4) - amino acid metabolism

### 2. **Glucose-6-phosphate dehydrogenase** (EC 1.1.1.49)
- First enzyme of pentose phosphate pathway
- Can use both NAD+ and NADP+

### 3. **Pyruvate dehydrogenase complex** (EC 1.2.4.1)
- Converts pyruvate to acetyl-CoA
- Uses NAD+ as electron acceptor

### 4. **Formate dehydrogenase** (EC 1.2.1.2)
- Oxidizes formate to CO2

### 5. **Aldehyde dehydrogenases** (EC 1.2.1.x)
- Oxidize aldehydes to carboxylic acids

These enzymes all belong to **EC class 1 (Oxidoreductases)** and use NAD+ as an electron acceptor, reducing it to NADH.",,7.886965990066528,57,521,True,True,0.6666666666666666,"Based on my search through multiple biological databases, I found extensive information about **enzymes that catalyze oxidoreductase reactions using NAD+ as a cofactor**. Here's a comprehensive summary:

## Overview
These enzymes belong to **EC class 1 (oxidoreductases)** and use NAD+ (nicotinamide adenine dinucleotide) as an electron acceptor, reducing it to NADH while oxidizing their substrates.

## Major Enzyme Categories

### 1. **Dehydrogenases** (Most Common)
These are the primary NAD+-dependent oxidoreductases:

- **Lactate Dehydrogenase (EC 1.1.1.27)**
  - Converts (R)-lactate to pyruvate
  - Reaction: (R)-lactate + NAD+ = pyruvate + NADH + H+

- **Alcohol Dehydrogenases**
  - Convert alcohols to aldehydes/ketones
  - Example: 3-methylbutan-1-ol + NAD+ = 3-methylbutanal + NADH + H+

- **Malate Dehydrogenase**
  - Key enzyme in citric acid cycle
  - Converts malate to oxaloacetate

- **Isocitrate Dehydrogenase (NAD+) (EC 1.1.1.41)**
  - Part of citric acid cycle
  - Though NADP+-dependent forms are more common (EC 1.1.1.42)

- **Glutamate Dehydrogenase**
  - Reaction: 2 L-glutamate + NAD+ = L-glutamine + 2-oxoglutarate + NADH + H+

- **Glucose Dehydrogenase (EC 1.1.1.47)**
  - Reaction: D-glucose + NAD+ = D-glucono-1,5-lactone + NADH + H+

### 2. **Aldehyde Dehydrogenases**
- **Benzaldehyde Dehydrogenase**
  - Reaction: benzaldehyde + NAD+ + H2O = benzoate + NADH + 2 H+
  
- **4-Hydroxybenzaldehyde Dehydrogenase**
  - Reaction: 4-hydroxybenzaldehyde + NAD+ + H2O = 4-hydroxybenzoate + NADH + 2 H+

- **Long-chain Fatty Aldehyde Dehydrogenases**
  - Convert fatty aldehydes to fatty acids

### 3. **Steroid Dehydrogenases**
- **17β-Hydroxysteroid Dehydrogenase**
  - Reaction: 17beta-estradiol + NAD+ = estrone + NADH + H+

- **Testosterone Dehydrogenase**
  - Reaction: testosterone + NAD+ = androst-4-ene-3,17-dione + NADH + H+

- **11β-Hydroxysteroid Dehydrogenases**
  - Involved in cortisol/cortisone interconversion

### 4. **NADH Dehydrogenase (Complex I)**
Multiple subunits found in mitochondrial electron transport:
- **NADH-ubiquinone oxidoreductase (EC 7.1.1.2)**
  - Transfers electrons from NADH to ubiquinone
  - Reaction: NADH + ubiquinone + 5 H+(in) = NAD+ + ubiquinol + 4 H+(out)
  - Key proteins: NDUFA9, NDUFV1, NDUFV2 (multiple subunits)

### 5. **Specialized Oxidoreductases**
- **Xanthine Dehydrogenase (EC 1.17.1.4)**
  - Reaction: xanthine + NAD+ + H2O = urate + NADH + H+

- **Hypoxanthine Dehydrogenase**
  - Reaction: hypoxanthine + NAD+ + H2O = xanthine + NADH + H+

- **Arogenate Dehydrogenase**
  - Reaction: L-arogenate + NAD+ = L-tyrosine + CO2 + NADH

- **Cysteine Dehydrogenase**
  - Reaction: 2 L-cysteine + NAD+ = L-cystine + NADH + H+

## Gene Ontology Classification

**GO:0016651** - ""oxidoreductase activity, acting on NAD(P)H""
- Catalysis of redox reactions where NADH or NADPH acts as hydrogen/electron donor

Related terms:
- GO:0003954 - NADH dehydrogenase activity
- GO:0008137 - NADH dehydrogenase (ubiquinone) activity
- GO:0016668 - oxidoreductase activity, acting on sulfur groups with NAD(P) as acceptor

## Example Proteins from UniProt

**Human enzymes:**
- **P28331** - NADH-ubiquinone oxidoreductase 75 kDa subunit (Complex I-75kD)
- **P49821** - NADH dehydrogenase flavoprotein 1 (NDUFV1)
- **P19404** - NADH dehydrogenase flavoprotein 2 (NDUFV2)
- **P15559** - NAD(P)H dehydrogenase [quinone] 1 (Quinone reductase)

## Functional Importance

These NAD+-dependent oxidoreductases are crucial for:
1. **Energy metabolism** - Citric acid cycle, electron transport chain
2. **Metabolic pathways** - Amino acid, lipid, and carbohydrate metabolism
3. **Detoxification** - Aldehyde and xenobiotic metabolism
4. **Hormone metabolism** - Steroid interconversions
5. **Redox homeostasis** - Maintaining cellular NAD+/NADH balance

The NAD+/NADH couple has a redox potential that makes it ideal for accepting electrons from a wide variety of substrates, which is why NAD+-dependent oxidoreductases are among the most abundant and diverse enzyme classes in biology.",,65.89158606529236,27,2630,29332,183851,"mcp__ols__search, mcp__togomcp__search_rhea_entity, mcp__togomcp__search_uniprot_entity, mcp__ols__searchClasses, mcp__pubdictionaries__find_ids, mcp__togomcp__get_MIE_file, mcp__togomcp__run_sparql, mcp__togomcp__run_sparql, mcp__ols__fetch","[{""name"": ""mcp__ols__search"", ""input"": {""query"": ""oxidoreductase NAD cofactor""}}, {""name"": ""mcp__togomcp__search_rhea_entity"", ""input"": {""query"": ""NAD+ oxidoreductase"", ""limit"": 50}}, {""name"": ""mcp__togomcp__search_uniprot_entity"", ""input"": {""query"": ""NAD+ oxidoreductase"", ""limit"": 20}}, {""name"": ""mcp__ols__searchClasses"", ""input"": {""query"": ""oxidoreductase NAD"", ""ontologyId"": ""go"", ""pageSize"": 20}}, {""name"": ""mcp__pubdictionaries__find_ids"", ""input"": {""labels"": ""lactate dehydrogenase, alcohol dehydrogenase, malate dehydrogenase, isocitrate dehydrogenase, glutamate dehydrogenase"", ""dictionary"": ""MESH""}}, {""name"": ""mcp__togomcp__get_MIE_file"", ""input"": {""dbname"": ""uniprot""}}, {""name"": ""mcp__togomcp__run_sparql"", ""input"": {""dbname"": ""rhea"", ""sparql_query"": ""PREFIX rh: <http://rdf.rhea-db.org/>\nPREFIX rdfs: <http://www.w3.org/2000/01/rdf-schema#>\n\nSELECT DISTINCT ?reaction ?equation ?ecNumber\nWHERE {\n  ?reaction rh:equation ?equation ;\n            rh:ec ?ec .\n  ?ec rdfs:label ?ecNumber .\n  FILTER (CONTAINS(?equation, \""NAD(+)\""))\n  FILTER (regex(?ecNumber, \""^1\\\\.\""))\n}\nLIMIT 30""}}, {""name"": ""mcp__togomcp__run_sparql"", ""input"": {""dbname"": ""rhea"", ""sparql_query"": ""PREFIX rh: <http://rdf.rhea-db.org/>\nPREFIX rdfs: <http://www.w3.org/2000/01/rdf-schema#>\n\nSELECT DISTINCT ?rheaId ?equation ?ecLabel\nWHERE {\n  ?reaction rh:accession ?rheaId ;\n            rh:equation ?equation ;\n            rh:ec ?ec .\n  ?ec rdfs:label ?ecLabel .\n  FILTER (CONTAINS(STR(?equation), \""NAD(+)\""))\n  FILTER (regex(?ecLabel, \""^1\\\\.\""))\n}\nLIMIT 25""}}, {""name"": ""mcp__ols__fetch"", ""input"": {""id"": ""go+http://purl.obolibrary.org/obo/GO_0016651""}}]",VALUABLE,List of oxidoreductase enzymes (EC 1.x.x.x) that use NAD+ (CHEBI:57540) in their reactions,"COMPLEX QUERY requiring EC class and compound knowledge.

Databases/Resources: Rhea, UniProt, ChEBI

Knowledge Required:
- EC class 1 for oxidoreductases
- NAD+ ChEBI ID: CHEBI:57540
- Compound-reaction linkage via rdfs:subClassOf
- Cross-database join via EC numbers
- up:reviewed 1 filter for performance

Without proper knowledge: Cannot combine EC classification with compound filtering.

Verified in rhea_exploration.md (complex filtering questions)."
74,2026-01-31,Structured Query,What protein structures contain both protein and DNA components?,True,True,True,1.0,"Protein-DNA complexes are structures that contain both protein and DNA components. Here are the main categories:

## **Nucleosomes**
The fundamental unit of chromatin, consisting of DNA wrapped around a histone octamer (8 histone proteins: 2 copies each of H2A, H2B, H3, and H4). About 147 base pairs of DNA wrap around this protein core in 1.65 turns.

## **Transcription Factor-DNA Complexes**
Proteins that bind to specific DNA sequences to regulate gene expression, including:
- Zinc finger proteins
- Helix-turn-helix proteins
- Leucine zipper proteins
- Basic helix-loop-helix (bHLH) proteins

## **DNA Polymerase Complexes**
Enzymes involved in DNA replication that bind to DNA template strands while synthesizing new DNA.

## **DNA Repair Protein Complexes**
Various enzymes that recognize and bind to damaged DNA, such as:
- Photolyases
- DNA glycosylases
- Excision repair complexes

## **Restriction Endonucleases**
Enzymes that recognize and bind to specific DNA sequences before cleaving the DNA.

## **Recombinases**
Proteins like RecA (in bacteria) or Rad51 (in eukaryotes) that bind to DNA during homologous recombination.

## **CRISPR-Cas Complexes**
Guide RNA-directed nucleases complexed with target DNA sequences.

These structures are essential for DNA packaging, gene regulation, replication, repair, and recombination processes in cells.",,8.475231885910034,47,379,True,True,0.6666666666666666,"Great! I found a large number of protein-DNA complexes. The search returned **35,335 structures** in the PDB that contain both protein and DNA components. Here are some notable examples:

## Representative Protein-DNA Complex Structures:

1. **1D66** - GAL4 transcription factor bound to DNA
   - Shows DNA recognition by the GAL4 protein

2. **3KXT** - Cren7-DNA complex from *Sulfolobus*
   - Archaeal chromatin protein bound to double-stranded DNA

3. **4OU7/4OU6** - DnaT protein with single-stranded DNA
   - Reveals novel single-stranded DNA binding modes

4. **1FYM/1FYK/1FYL** - Heat shock transcription factor DNA-binding domain
   - Multiple orientations of the protein-DNA complex

5. **2CGP** - Catabolite gene activator protein (CAP) with DNA
   - Classic example of transcriptional regulation

6. **1QRV** - HMG-D (High Mobility Group) protein with DNA
   - DNA-bending protein complex

7. **1LQ1** - Key transcription factor in bacterial sporulation
   - Important for developmental gene regulation

These structures represent various types of protein-DNA interactions including:
- **Transcription factors** binding to regulatory DNA sequences
- **DNA-binding domains** recognizing specific sequences
- **Chromatin proteins** organizing DNA
- **DNA replication/repair proteins** interacting with DNA

Would you like more details about any specific type of protein-DNA complex or a particular structure?",,21.301419973373413,9,514,1201,52648,mcp__togomcp__search_pdb_entity,"[{""name"": ""mcp__togomcp__search_pdb_entity"", ""input"": {""db"": ""pdb"", ""query"": ""protein DNA complex"", ""limit"": 20}}]",VALUABLE,"Protein-DNA complex structures such as nucleosome complexes, transcription factor-DNA complexes","COMPLEX QUERY requiring polymer type knowledge.

Databases/Resources: PDB

Knowledge Required:
- entity_poly category for polymer type
- Multiple polymer types in same entry
- HAVING clause for multiple conditions
- GROUP BY entry for aggregation

Without proper knowledge: Cannot identify multi-type entries correctly.

Verified in pdb_exploration.md Pattern 9 (Polymer Type Distribution)."
75,2026-01-31,Integration,What GO cellular components relate to lysosomal storage diseases?,True,True,True,0.5,"Lysosomal storage diseases (LSDs) are primarily associated with defects in lysosomal function, so the most relevant GO cellular components include:

## Primary Components:

1. **Lysosome (GO:0005764)** - The central organelle affected in all LSDs, where undegraded materials accumulate

2. **Lysosomal membrane (GO:0005765)** - Defects here can affect substrate transport and lysosomal integrity

3. **Lysosomal lumen (GO:0043202)** - Where most hydrolytic enzymes function and substrates accumulate

## Related Components:

4. **Vacuolar membrane (GO:0005774)** - In yeast models, equivalent to lysosomal membrane

5. **Endosome (GO:0005768)** - Part of the endolysosomal pathway; early and late endosomes are involved in trafficking to lysosomes

6. **Late endosome (GO:0005770)** - Directly precedes lysosomes in the degradation pathway

7. **Golgi apparatus (GO:0005794)** - Where lysosomal enzymes are modified and sorted (mannose-6-phosphate tagging)

8. **ER (GO:0005783)** - Where lysosomal enzymes are initially synthesized

9. **Autophagosome (GO:0005776)** - Delivers cytoplasmic cargo to lysosomes; impaired when lysosomal function is compromised

These components reflect the fact that LSDs involve not just lysosomes themselves, but the entire endomembrane system responsible for lysosomal biogenesis, enzyme trafficking, and substrate delivery.",,10.952907085418701,50,395,True,True,0.5833333333333334,"Based on my search of the Gene Ontology (GO) database, here are the key **GO cellular components** that relate to lysosomal storage diseases:

## Primary Lysosomal Components

**1. Lysosome (GO:0005764)**
- The main organelle affected in lysosomal storage diseases
- A small lytic vacuole containing hydrolases that function optimally at pH 5-6
- Contains about 40 different lysosomal hydrolases

**2. Lysosomal membrane (GO:0005765)**
- The lipid bilayer surrounding the lysosome
- Separates lysosomal contents from the cell cytoplasm
- Critical for maintaining lysosomal integrity and function

**3. Lysosomal lumen (GO:0043202)**
- The internal volume enclosed within the lysosomal membrane
- Where material accumulation occurs in storage diseases

## Specialized Lysosomal Subtypes

**4. Primary lysosome (GO:0005766)**
- Lysosome before fusion with other vesicles/vacuoles

**5. Secondary lysosome (GO:0005767)**
- Forms after fusion with organelles or phagosomes
- Includes subtypes:
  - **Autolysosome (GO:0044754)** - fuses with autophagosomes for autophagy
  - **Phagolysosome (GO:0032010)** - fuses with phagosomes

**6. Endolysosome (GO:0036019)**
- Transient hybrid organelle formed by fusion of late endosome with lysosome
- Site of active degradation

## Related Components

**7. Lysosomal matrix (GO:1990836)**
- Supramolecular assemblies of lysosomal enzymes and lipids at pH 5.0

**8. BORC complex (GO:0099078)**
- Protein complex involved in lysosome positioning within the cytoplasm
- Recruits ARL8 to couple lysosomes to kinesin motors

## Clinical Relevance

These cellular components are directly relevant to lysosomal storage diseases because:
- **Defects in lysosomal enzymes** lead to accumulation of undegraded material in the lysosomal lumen
- **Membrane protein defects** can affect substrate transport
- **Impaired autophagy** (autolysosome dysfunction) contributes to disease pathology
- **Trafficking defects** can prevent proper enzyme delivery to lysosomes

The endosomal-lysosomal pathway components (endolysosomes, autolysosomes) are particularly important as many storage diseases involve disrupted material trafficking and degradation through these compartments.",,37.658552169799805,13,1138,33612,99860,"mcp__ols__search, mcp__ols__searchClasses, mcp__ols__fetch, mcp__ols__fetch, mcp__ols__fetch, mcp__ols__getDescendants","[{""name"": ""mcp__ols__search"", ""input"": {""query"": ""lysosomal storage disease""}}, {""name"": ""mcp__ols__searchClasses"", ""input"": {""query"": ""lysosome cellular component"", ""ontologyId"": ""go"", ""pageSize"": 20}}, {""name"": ""mcp__ols__fetch"", ""input"": {""id"": ""go+http://purl.obolibrary.org/obo/GO_0005764""}}, {""name"": ""mcp__ols__fetch"", ""input"": {""id"": ""go+http://purl.obolibrary.org/obo/GO_0005765""}}, {""name"": ""mcp__ols__fetch"", ""input"": {""id"": ""go+http://purl.obolibrary.org/obo/GO_0043202""}}, {""name"": ""mcp__ols__getDescendants"", ""input"": {""ontologyId"": ""go"", ""classIri"": ""http://purl.obolibrary.org/obo/GO_0005764"", ""pageSize"": 50}}]",VALUABLE,"GO cellular components (lysosome, mitochondrion) that keyword-match with lysosomal disease terms from MONDO","COMPLEX QUERY requiring cross-database integration.

Databases/Resources: GO, MONDO

Knowledge Required:
- Cross-database query on primary endpoint
- ^^xsd:string type restriction for namespace filter (critical)
- bif:contains for keyword matching
- MONDO graph URI and owl:Class type
- GO cellular_component namespace filter

Without proper knowledge: Namespace filter returns empty without type restriction.

Verified in go_exploration.md Pattern 4 (Cross-Database Query with Type Restriction)."
76,2026-01-31,Integration,What is the PubChem compound ID for aspirin?,True,True,True,1.0,"The PubChem compound ID (CID) for aspirin is **2244**.

Aspirin, also known as acetylsalicylic acid, is one of the most well-known pharmaceutical compounds and has this identifier in the PubChem database.",,2.0748298168182373,50,61,True,True,1.0,The PubChem compound ID (CID) for aspirin is **2244**.,,10.98554801940918,9,108,469,52651,mcp__togomcp__get_pubchem_compound_id,"[{""name"": ""mcp__togomcp__get_pubchem_compound_id"", ""input"": {""compound_name"": ""aspirin""}}]",VALUABLE,PubChem CID 2244,"SIMPLE QUERY - Straightforward compound lookup.

Method: get_pubchem_compound_id('aspirin')

Demonstrates when basic compound search tools suffice.

Verified through PubChem search capabilities."
77,2026-01-31,Completeness,How many RNA structures are deposited in the PDB?,True,False,False,0.3333333333333333,"I don't have access to real-time data about the current number of RNA structures in the Protein Data Bank (PDB), as my training data has a cutoff date and the PDB is continuously updated with new deposits.

However, I can tell you that:

1. As of my last training data (April 2024), there were approximately **4,000-5,000 RNA-only structures** in the PDB, though this number has been growing steadily.

2. If you include **structures containing RNA as part of complexes** (such as ribosomes, RNA-protein complexes, RNA-DNA hybrids, etc.), the number would be significantly higher - potentially 8,000-10,000+ entries.

3. RNA structures represent a much smaller fraction of the PDB compared to protein structures (which number over 200,000), partly because RNA can be more challenging to crystallize and study structurally.

For the most current and accurate number, I'd recommend checking the PDB website directly (rcsb.org or pdbe.org), where you can search and filter by molecule type to get up-to-date statistics.",,7.0513341426849365,49,253,True,False,0.3333333333333333,"Based on the search results from the Protein Data Bank (PDB), there are **82,015 RNA structures** deposited in the PDB.

This is a substantial number and includes various types of RNA structures such as:
- RNA quadruplexes
- RNA-protein complexes
- tRNA structures
- RNA aptamers
- RNA recognition motifs
- Ribosomal RNA structures
- And many other RNA-related macromolecular structures

The PDB search returned this total count when querying for ""RNA"" across all entries in the database.",,17.361579179763794,9,247,1103,52650,mcp__togomcp__search_pdb_entity,"[{""name"": ""mcp__togomcp__search_pdb_entity"", ""input"": {""db"": ""pdb"", ""query"": ""RNA"", ""limit"": 20}}]",CRITICAL,"13,539 polyribonucleotide (RNA) structures","COMPLEX QUERY requiring polymer type knowledge.

Databases/Resources: PDB

Knowledge Required:
- entity_poly category for polymer classification
- entity_poly.type = 'polyribonucleotide' for RNA
- COUNT DISTINCT for unique entities
- FROM graph clause

Without proper knowledge: Cannot identify RNA structures correctly.

Verified in pdb_exploration.md Pattern 9."
78,2026-01-31,Completeness,How many reactions in Rhea have EC number annotations?,True,False,False,0.25,"I don't have specific training data about the exact number of reactions in Rhea that have EC number annotations. 

However, I can tell you that Rhea is a comprehensive database of biochemical reactions that is expert-curated and closely integrated with the Enzyme Commission (EC) classification system. A significant portion of Rhea reactions do have EC number annotations, as one of Rhea's primary purposes is to provide a standard vocabulary for enzyme-catalyzed reactions that maps to EC numbers.

The exact count would vary depending on when you're asking, as Rhea is continuously updated and curated. To get the current, accurate number, you would need to query the Rhea database directly or check their latest statistics on their website.",,5.1490678787231445,49,160,True,True,0.5,"Based on my query of the Rhea database, **7,434 reactions have EC number annotations**.

To put this in context:
- Rhea contains 17,078 total reactions (master reactions)
- This means approximately **43.5%** of Rhea reactions have EC (Enzyme Commission) number annotations
- These EC numbers link reactions to enzyme classifications and enable cross-referencing with protein databases like UniProt

The EC numbers in Rhea use the property `rhea:ec` and link to the UniProt enzyme namespace (e.g., `http://purl.uniprot.org/enzyme/3.5.1.50`), which allows for powerful integration between biochemical reactions and the proteins that catalyze them.",,18.867527961730957,15,452,12380,90978,"mcp__togomcp__get_MIE_file, mcp__togomcp__run_sparql","[{""name"": ""mcp__togomcp__get_MIE_file"", ""input"": {""dbname"": ""rhea""}}, {""name"": ""mcp__togomcp__run_sparql"", ""input"": {""dbname"": ""rhea"", ""sparql_query"": ""PREFIX rdfs: <http://www.w3.org/2000/01/rdf-schema#>\nPREFIX rhea: <http://rdf.rhea-db.org/>\n\nSELECT (COUNT(DISTINCT ?reaction) as ?count)\nWHERE {\n  ?reaction rdfs:subClassOf rhea:Reaction ;\n            rhea:ec ?ec .\n}""}}]",CRITICAL,"7,432 reactions (44.5% of approved reactions)","SIMPLE QUERY - Straightforward count with EC filter.

Method: Simple SPARQL COUNT with rhea:ec filter

Demonstrates a straightforward completeness query.

Verified in rhea_exploration.md (Dataset Size section)."
79,2026-01-31,Specificity,What variants in the CFTR gene are associated with cystic fibrosis?,True,True,True,0.5,"The CFTR (Cystic Fibrosis Transmembrane Conductance Regulator) gene has over 2,000 identified variants associated with cystic fibrosis, but here are the most significant ones:

## Most Common Variants:

**F508del (ΔF508)**
- The most common CF-causing variant worldwide
- Accounts for approximately 70% of CF alleles globally
- Results in deletion of phenylalanine at position 508
- Causes protein misfolding and degradation

## Other Common Variants:

**G542X** - A nonsense mutation creating a premature stop codon

**G551D** - A missense mutation affecting chloride channel gating

**N1303K** - Common in certain populations, affects protein processing

**W1282X** - Particularly common in Ashkenazi Jewish populations

**R117H** - Associated with milder phenotypes and variable disease severity

**621+1G→T** - A splicing mutation

**R553X** - Another nonsense mutation

## Variant Classes:

CFTR variants are classified into 6 classes based on their mechanism:
- **Class I**: No protein synthesis (nonsense, frameshift)
- **Class II**: Protein processing defects (F508del)
- **Class III**: Gating defects (G551D)
- **Class IV**: Reduced conductance
- **Class V**: Reduced protein quantity
- **Class VI**: Reduced stability

The specific variants a person carries significantly influence disease severity and treatment options, particularly with newer CFTR modulator therapies.",,9.933935165405273,55,367,True,True,0.5,"Based on the comprehensive database searches, I can provide you with detailed information about CFTR gene variants associated with cystic fibrosis.

## CFTR Variants Associated with Cystic Fibrosis

**Overview:**
The CFTR (Cystic Fibrosis Transmembrane Conductance Regulator) gene is located on chromosome 7 (7q31.2) and encodes a chloride channel protein. According to ClinVar, there are **over 5,500 documented variants** in the CFTR gene associated with cystic fibrosis.

### Most Common Variant

**F508del (Phe508del)** - This is the most prevalent CF-causing mutation worldwide, accounting for approximately 70-90% of CF chromosomes in patients of European descent. This is a deletion mutation that removes a phenylalanine residue at position 508 of the CFTR protein.

### Recent Variants from ClinVar

Here are some recently documented CFTR variants with their classifications:

**Pathogenic/Uncertain Significance Missense Variants:**

1. **p.Ala1285Glu** (c.3854_3855delinsAA) - Uncertain significance
2. **p.Phe1164Leu** (c.3490T>C) - Uncertain significance
3. **p.Pro988Ser** (c.2962C>T) - Uncertain significance
4. **p.Arg697Thr** (c.2090G>C) - Uncertain significance
5. **p.Leu1261Pro** (c.3782T>C) - Uncertain significance
6. **p.Ala1374Pro** (c.4120G>C) - Uncertain significance
7. **p.Glu535Gln** (c.1603G>C) - Uncertain significance
8. **p.Pro1306Leu** (c.3917C>T) - Uncertain significance

**Likely Benign Synonymous Variants:**

1. **p.Cys343=** (c.1029C>T) - Likely benign (synonymous, no amino acid change)
2. **p.Arg555=** (c.1665A>G) - Likely benign (synonymous)

### Clinical Variant Example

According to a recent case report from PubMed, a Japanese man was diagnosed with CF due to a **homozygous c.1210-11 T>G variant** in the CFTR gene, which manifested as congenital bilateral absence of the vas deferens (CBAVD) and recurrent pancreatitis ([DOI](https://doi.org/10.1002/rmb2.70018)).

### Treatment Advances

According to PubMed research, **CFTR modulators** represent a therapeutic revolution for cystic fibrosis. These drugs bind to the CFTR protein to improve its function and are now available for more than 85% of patients. The effectiveness depends on which specific variants patients carry ([DOI](https://doi.org/10.1007/s12551-025-01350-6)).

The variants cause different molecular consequences including:
- Missense variants (amino acid substitutions)
- Deletions (like F508del)
- Splice site variants
- Synonymous variants (usually benign)

Would you like more information about any specific variant or aspect of CFTR-related cystic fibrosis?",,45.72366118431091,24,1584,17732,123619,"mcp__togomcp__search_uniprot_entity, mcp__togomcp__search_ncbigene, mcp__togomcp__ncbi_esearch, mcp__pubmed__search_articles, mcp__togomcp__ncbi_esummary, mcp__pubmed__get_article_metadata, mcp__togomcp__ncbi_esearch, mcp__pubmed__search_articles","[{""name"": ""mcp__togomcp__search_uniprot_entity"", ""input"": {""query"": ""CFTR cystic fibrosis transmembrane conductance regulator human"", ""limit"": 5}}, {""name"": ""mcp__togomcp__search_ncbigene"", ""input"": {""query"": ""CFTR AND human[organism]"", ""max_results"": ""5""}}, {""name"": ""mcp__togomcp__ncbi_esearch"", ""input"": {""database"": ""clinvar"", ""query"": ""CFTR[gene] AND cystic fibrosis"", ""max_results"": 20}}, {""name"": ""mcp__pubmed__search_articles"", ""input"": {""query"": ""CFTR gene variants cystic fibrosis"", ""max_results"": 10}}, {""name"": ""mcp__togomcp__ncbi_esummary"", ""input"": {""database"": ""clinvar"", ""ids"": [""4683093"", ""4652928"", ""4652059"", ""4651969"", ""4651878"", ""4651784"", ""4651695"", ""4651604"", ""4651520"", ""4651433""]}}, {""name"": ""mcp__pubmed__get_article_metadata"", ""input"": {""pmids"": [""41613863"", ""41575084"", ""41574047""]}}, {""name"": ""mcp__togomcp__ncbi_esearch"", ""input"": {""database"": ""clinvar"", ""query"": ""CFTR[gene] AND F508del"", ""max_results"": 5}}, {""name"": ""mcp__pubmed__search_articles"", ""input"": {""query"": ""CFTR F508del cystic fibrosis most common mutation"", ""max_results"": 5}}]",VALUABLE,CFTR variants including the common p.Phe508del (VCV000007105) and many other disease-associated variants,"COMPLEX QUERY requiring gene-disease association knowledge.

Databases/Resources: ClinVar

Knowledge Required:
- Gene-based variant filtering
- Disease association via med2rdf:disease
- bif:contains for gene name search
- record_status and significance filtering

Without proper knowledge: Cannot navigate gene-disease-variant relationships.

Verified in clinvar_exploration.md."
80,2026-01-31,Specificity,What are the synonyms for the GO term 'nucleus' (GO:0005634)?,True,False,True,0.5714285714285714,"I don't have access to the complete synonym list for GO:0005634 (nucleus) in my training data. However, I can tell you that Gene Ontology terms typically have synonyms that include:

For the nucleus term, common synonyms historically included terms like:
- Cell nucleus
- Horsetail nucleus (a specific related term)

Gene Ontology terms can have multiple types of synonyms (exact, broad, narrow, and related), but I cannot provide you with the definitive, complete list of all synonyms for GO:0005634 without accessing the actual GO database or current GO files.

For the most accurate and up-to-date list of synonyms for this term, I would recommend:
1. Visiting the Gene Ontology website (geneontology.org)
2. Using the AmiGO browser
3. Checking the QuickGO database at EBI
4. Downloading the current GO OBO or OWL file

I apologize that I cannot give you the complete synonym list with certainty from my training knowledge alone.",,6.27810001373291,57,238,True,False,0.14285714285714285,"Based on my queries to the OLS (Ontology Lookup Service), I found information about GO:0005634 (nucleus), but the OLS MCP tools are not returning synonym information in their responses. The available data includes:

**GO:0005634 - nucleus**

**Definition:** A membrane-bounded organelle of eukaryotic cells in which chromosomes are housed and replicated. In most cells, the nucleus contains all of the cell's chromosomes except the organellar chromosomes, and is the site of RNA synthesis and processing. In some species, or in specialized cell types, RNA metabolism or DNA replication may be absent.

Unfortunately, the synonym information is not being returned by the current MCP tool queries. However, based on standard GO annotations, the GO term for ""nucleus"" (GO:0005634) typically has the following **exact synonym**:
- **cell nucleus**

For more complete synonym information, you may want to access the GO term directly through the Gene Ontology website (https://www.ebi.ac.uk/QuickGO/term/GO:0005634) or download the full GO ontology file which contains all synonym annotations.",,26.88230800628662,16,574,3212,107294,"mcp__ols__fetch, mcp__ols__searchClasses, mcp__ols__search","[{""name"": ""mcp__ols__fetch"", ""input"": {""id"": ""go+http://purl.obolibrary.org/obo/GO_0005634""}}, {""name"": ""mcp__ols__searchClasses"", ""input"": {""query"": ""GO:0005634"", ""ontologyId"": ""go""}}, {""name"": ""mcp__ols__search"", ""input"": {""query"": ""nucleus GO:0005634""}}]",CRITICAL,Synonyms for nucleus including 'cell nucleus' and related terms,"SIMPLE QUERY - Straightforward synonym lookup.

Method: OLS4 fetch for GO:0005634 or SPARQL query for synonyms

Demonstrates when basic ontology lookup tools suffice.

Verified in go_exploration.md simple queries section."
81,2026-01-31,Currency,What membrane protein structures have been determined by cryo-electron microscopy?,True,True,True,1.0,"Cryo-electron microscopy (cryo-EM) has revolutionized membrane protein structural biology, determining structures of numerous important proteins and complexes. Here are major categories and examples:

## **Ion Channels and Transporters**

- **TRP channels** (TRPV1, TRPA1, TRPM4, TRPP2)
- **Voltage-gated channels** (Nav, Cav, Kv channels)
- **Ryanodine receptors** (RyR1, RyR2)
- **NMDA and AMPA receptors**
- **ABC transporters** (P-glycoprotein, CFTR)
- **Aquaporins**
- **Calcium pumps** (SERCA)
- **Sodium-potassium ATPase**

## **G Protein-Coupled Receptors (GPCRs)**

- Multiple GPCRs in complex with G proteins or arrestins
- β-adrenergic receptors
- Muscarinic receptors
- Glucagon receptor complexes

## **Large Membrane Complexes**

- **Respiratory chain complexes** (Complex I, II, III, IV, and supercomplexes)
- **Photosynthetic complexes** (photosystems I and II)
- **ATP synthase**
- **Cytochrome bc1 complex**

## **Receptors and Signaling**

- **Ligand-gated ion channels** (nicotinic acetylcholine receptor, glycine receptor)
- **Receptor tyrosine kinases**
- **Notch receptor**

## **Viral Membrane Proteins**

- **Spike proteins** (including SARS-CoV-2)
- **Influenza hemagglutinin**
- **HIV envelope proteins**

## **Other Notable Structures**

- **Gap junction channels** (connexins, innexins)
- **Mechanosensitive channels**
- **Nuclear pore complex** (transmembrane components)

Cryo-EM has been particularly powerful for large, flexible membrane protein complexes that are difficult to crystallize.",,11.507667064666748,52,502,True,True,0.875,"Excellent! The search found **6,641 membrane protein structures** determined by cryo-electron microscopy in the PDB database. Here are some notable examples from the results:

## Major Categories of Membrane Proteins Determined by Cryo-EM:

### **1. Ion Channels & Transporters**
- **TRPV2 and TRPML3** - TRP ion channels involved in sensory perception and cellular signaling
- **CLC-K chloride channels** - Important for ion transport
- **ABC transporters** (ABCB1/P-glycoprotein, ABCB6) - Drug efflux pumps and transporters
- **CLHM1** - Chloride channel homolog

### **2. Viral Membrane Proteins**
- **SARS-CoV-2 spike proteins** - Multiple structures including variants (N501Y mutant) and antibody complexes
- **SARS-CoV spike glycoproteins** - Earlier coronavirus structures
- **Dengue virus membrane proteins** - Flavivirus envelope structures
- **SARS-CoV-2 M protein** - Membrane protein dimers in various complexes

### **3. Protein Translocation Machinery**
- **YidC insertase** - Membrane protein insertase bound to ribosome
- **Human ribosome-TMCO1 translocon** - Protein translocation complex
- **SecY translocon** - Membrane insertion machinery
- **ER membrane protein complex** - Involved in membrane protein biogenesis

### **4. Glycosylation Machinery**
- **Human oligosaccharyltransferase complexes** (OST-A and OST-B) - Critical for N-linked glycosylation

### **5. Bacterial Secretion Systems**
- **Type III and Type VI secretion systems** - Bacterial protein export machinery
- **Apolipoprotein N-acyltransferase (Lnt)** - Lipoprotein modification enzyme

### **6. Other Notable Examples**
- **Bacteriophage coat proteins** (f1, IKe phages) - Filamentous virus structures
- **PREX1** - Phosphatidylinositol-dependent Rac exchanger

This represents a massive collection spanning diverse biological functions including signal transduction, drug resistance, viral infection, protein trafficking, and bacterial pathogenesis. Cryo-EM has revolutionized membrane protein structural biology by enabling structure determination without requiring crystals, which is particularly advantageous for these challenging targets.",,24.384918928146362,9,728,2420,52653,mcp__togomcp__search_pdb_entity,"[{""name"": ""mcp__togomcp__search_pdb_entity"", ""input"": {""db"": ""pdb"", ""query"": ""membrane protein cryo-electron microscopy"", ""limit"": 50}}]",VALUABLE,"Cryo-EM membrane protein structures including ion channels, transporters, and receptors","COMPLEX QUERY requiring method and classification filtering.

Databases/Resources: PDB

Knowledge Required:
- exptl.method = 'ELECTRON MICROSCOPY' filter
- struct_keywords for 'membrane' classification
- CONTAINS filter for keyword matching
- FROM graph clause

Without proper knowledge: Cannot combine method and classification filters.

Verified in pdb_exploration.md (complex filtering patterns)."
82,2026-01-31,Currency,What clinical-stage kinase inhibitors are being developed for cancer?,True,False,True,0.5555555555555556,"I can provide information about some clinical-stage kinase inhibitors in cancer development, though this is a rapidly evolving field and my knowledge has a cutoff date:

## Notable Clinical-Stage Kinase Inhibitors:

**CDK Inhibitors:**
- Trilaciclib (CDK4/6) - was in clinical trials for various cancers
- Various selective CDK inhibitors targeting CDK2, CDK7, CDK9

**BTK Inhibitors:**
- Pirtobrutinib (non-covalent BTK inhibitor) - for B-cell malignancies
- Nemtabrutinib and other next-generation BTK inhibitors

**KRAS Inhibitors:**
- Adagrasib (KRAS G12C inhibitor) - for NSCLC and other solid tumors
- Various other KRAS G12C and G12D inhibitors in development

**FGFR Inhibitors:**
- Futibatinib - for cholangiocarcinoma
- Lirafugratinib and others for FGFR-altered cancers

**PI3K Inhibitors:**
- Eganelisib and other isoform-selective PI3K inhibitors

**Other Targets:**
- Aurora kinase inhibitors
- CHK1/2 inhibitors
- PARP-kinase combination approaches
- Various multi-kinase inhibitors

**Important Note:** The clinical trial landscape changes frequently with new candidates entering trials and others advancing or being discontinued. For current, specific information about which compounds are in which trial phases, you would need to consult clinical trial databases like ClinicalTrials.gov or recent pharmaceutical pipeline reports.

Is there a specific kinase target or cancer type you're most interested in?",,10.019253015518188,51,406,True,True,0.6666666666666666,"Based on the comprehensive search of PubMed and biological databases, I can provide you with information about clinical-stage kinase inhibitors being developed for cancer. Here's a summary of the most recent developments:

## Clinical-Stage Kinase Inhibitors for Cancer

According to PubMed, there are numerous kinase inhibitors currently in various stages of clinical development for cancer treatment. Here are some key examples organized by target and cancer type:

### **BTK (Bruton Tyrosine Kinase) Inhibitors**

1. **Zanubrutinib** - Advanced clinical use for chronic lymphocytic leukemia (CLL)
   - Showing improved progression-free survival compared to ibrutinib and acalabrutinib
   - Particularly effective in del(17p) and/or TP53 mutated CLL
   - [Study details](https://doi.org/10.1080/13696998.2025.2609514)
   - [High-risk population study](https://doi.org/10.1182/bloodadvances.2025015986)

2. **Ibrutinib** - Being studied in combination with CAR T-cell therapy
   - Phase 1b trial combining with tisagenlecleucel in relapsed/refractory large B-cell lymphomas
   - [Study link](https://doi.org/10.1016/j.bneo.2025.100176)

### **EGFR (Epidermal Growth Factor Receptor) TKIs**

3. **Dacomitinib** - Second-generation irreversible EGFR TKI
   - First-line therapy for EGFR mutation-positive advanced NSCLC
   - Real-world data showing median PFS of 20.1 months in Asian patients
   - [Real-world study](https://doi.org/10.1016/j.lungcan.2025.108856)

4. **Lorlatinib** - Third-generation ALK/ROS1 TKI
   - Phase 2 trial in TKI-naive ROS1-positive NSCLC
   - Impressive 73% objective response rate with median PFS of 53.6 months
   - Brain-penetrant with manageable safety profile
   - [Study results](https://doi.org/10.1001/jamaoncol.2025.5097)

5. **Osimertinib** - Being studied in novel combinations
   - TROPION-Lung15 phase 3 trial combining with datopotamab deruxtecan for EGFR-mutated NSCLC after osimertinib progression
   - [Protocol](https://doi.org/10.1177/17588359251385410)

### **VEGFR (Vascular Endothelial Growth Factor Receptor) Inhibitors**

6. **Lenvatinib** - Multi-kinase inhibitor
   - Effective but with notable toxicities across various cancers
   - Meta-analysis of toxicity profile
   - [Safety analysis](https://doi.org/10.1080/07853890.2025.2598935)

7. **Fruquintinib** - Selective VEGFR 1, 2, and 3 inhibitor
   - Phase 2 trial in microsatellite-stable metastatic colorectal cancer
   - Combined with sintilimab (anti-PD-1) and electroacupuncture
   - 21.4% ORR with improved safety profile
   - [Study details](https://doi.org/10.1016/j.canlet.2026.218238)

8. **Regorafenib** - Multi-kinase inhibitor
   - Phase 2 PARERE study for chemorefractory metastatic colorectal cancer
   - Studied in sequence with panitumumab
   - [Trial results](https://doi.org/10.1016/j.annonc.2025.10.002)

### **HER2-Targeted TKIs**

9. **Pyrotinib** - HER2 TKI
   - Phase 2 study in HR-negative/HER2-positive breast cancer
   - Combined with trastuzumab and dalpiciclib (CDK4/6 inhibitor) in chemotherapy-free neoadjuvant regimen
   - 63.3% total pathological complete response rate
   - [Study link](https://doi.org/10.1097/JS9.0000000000003328)

10. **Tucatinib** - HER2-selective TKI
    - TUTOR trial (phase 1) combining with trastuzumab, capecitabine, and stereotactic radiosurgery
    - For HER2-positive breast cancer brain metastases
    - [Protocol](https://doi.org/10.1186/s12885-025-15224-3)

### **AKT Inhibitors**

11. **Capivasertib** - Pan-AKT inhibitor
    - CAPItello-290 phase 3 trial in metastatic triple-negative breast cancer
    - Combined with paclitaxel as first-line treatment
    - Showed numerical PFS benefit but did not meet OS endpoint
    - [Results](https://doi.org/10.1016/j.annonc.2025.12.012)

### **CDK4/6 Inhibitors**

12. **Dalpiciclib** - CDK4/6 inhibitor
    - Being studied in multiple combinations including with HER2-targeted therapies
    - SONIA trial evaluating optimal sequencing in advanced breast cancer
    - [Cost-effectiveness study](https://doi.org/10.1016/j.ejca.2025.116051)

### **Key Trends in Clinical Development:**

1. **Combination strategies** - Many trials are exploring kinase inhibitors combined with:
   - Immunotherapy (checkpoint inhibitors)
   - Chemotherapy
   - Other targeted therapies
   - Radiation therapy

2. **Resistance mechanisms** - Multiple trials addressing acquired resistance to first-generation TKIs

3. **Biomarker-driven selection** - Use of circulating tumor DNA and molecular profiling to select patients

4. **Brain metastases** - Several studies specifically targeting CNS disease with brain-penetrant kinase inhibitors

5. **Safety optimization** - Focus on managing toxicity through dose modifications and sequencing strategies

These studies represent the cutting edge of kinase inhibitor development in oncology, with many showing promising efficacy while investigators work to optimize safety profiles and patient selection strategies.",,64.81368780136108,61,2364,35054,165312,"mcp__pubmed__search_articles, mcp__chembl__search_chembl_molecule, mcp__pubmed__get_article_metadata, mcp__togomcp__search_chembl_molecule, mcp__pubmed__search_articles, mcp__togomcp__search_chembl_target, mcp__pubmed__get_article_metadata, WebSearch","[{""name"": ""mcp__pubmed__search_articles"", ""input"": {""query"": ""kinase inhibitors cancer clinical trial"", ""max_results"": 20, ""date_from"": ""2022"", ""sort"": ""pub_date""}}, {""name"": ""mcp__chembl__search_chembl_molecule"", ""input"": {""query"": ""kinase inhibitor cancer clinical"", ""limit"": ""20""}}, {""name"": ""mcp__pubmed__get_article_metadata"", ""input"": {""pmids"": [""41553230"", ""41439769"", ""41485683"", ""40829104"", ""41536778"", ""41520595"", ""41423066"", ""41396392""]}}, {""name"": ""mcp__togomcp__search_chembl_molecule"", ""input"": {""query"": ""kinase inhibitor"", ""limit"": 20}}, {""name"": ""mcp__pubmed__search_articles"", ""input"": {""query"": ""kinase inhibitor phase 2 phase 3 cancer 2024 2025"", ""max_results"": 20, ""date_from"": ""2024"", ""sort"": ""pub_date""}}, {""name"": ""mcp__togomcp__search_chembl_target"", ""input"": {""query"": ""kinase cancer"", ""limit"": 20}}, {""name"": ""mcp__pubmed__get_article_metadata"", ""input"": {""pmids"": [""41365111"", ""41296331"", ""41115464"", ""40968745"", ""41466843"", ""41422862"", ""41207182"", ""41339822""]}}, {""name"": ""WebSearch"", ""input"": {""query"": ""FDA approved kinase inhibitors cancer 2024 2025 clinical trials""}}]",CRITICAL,Kinase inhibitors in clinical trials (Phase 2+) for cancer indications from ChEMBL,"COMPLEX QUERY requiring drug-target-indication knowledge.

Databases/Resources: ChEMBL

Knowledge Required:
- DrugIndication for cancer indication filtering
- Target filtering for kinases via bif:contains
- highestDevelopmentPhase >= 2 for clinical stage
- Cross-entity joins (molecule-target-indication)

Without proper knowledge: Cannot combine target type with indication data.

Verified in chembl_exploration.md Patterns 2, 4, 5."
83,2026-01-31,Precision,What is the number of submitters for the most well-supported ClinVar variant?,True,False,False,0.25,"I don't have access to real-time ClinVar data or the ability to query databases, so I cannot tell you the exact current number of submitters for the most well-supported variant.

However, I can provide some context: ClinVar variants that are well-supported typically have submissions from multiple laboratories and organizations. Historically, some of the most well-studied and clinically significant variants (such as common pathogenic variants in genes like BRCA1, BRCA2, or CFTR) have had submissions from dozens to over 100 different submitters.

The variant with the most submitters changes over time as new submissions are added to ClinVar. To find the current answer, you would need to:
1. Query the ClinVar database directly
2. Sort variants by number of submitters
3. Identify which has the maximum count

If you need this specific information, I'd recommend checking the ClinVar website or downloading their latest data release.",,7.067386865615845,55,210,True,True,0.75,"Perfect! I found the answer.

The **most well-supported ClinVar variant** (based on number of submitters) has **80 submitters**.

This variant is:
- **Variant ID**: VCV000017004
- **Description**: NM_004004.6(GJB2):c.35del (p.Gly12fs)
- **Type**: Deletion
- **Gene**: GJB2 (Gap Junction Beta 2 protein, also known as Connexin 26)

This deletion in the GJB2 gene is a well-known pathogenic variant associated with hereditary hearing loss and is one of the most commonly reported genetic variants in ClinVar due to its clinical significance and prevalence in population studies.",,21.78639578819275,15,523,37246,63382,"mcp__togomcp__get_MIE_file, mcp__togomcp__run_sparql","[{""name"": ""mcp__togomcp__get_MIE_file"", ""input"": {""dbname"": ""clinvar""}}, {""name"": ""mcp__togomcp__run_sparql"", ""input"": {""dbname"": ""clinvar"", ""sparql_query"": ""PREFIX cvo: <http://purl.jp/bio/10/clinvar/>\n\nSELECT ?variant ?label ?accession ?num_submitters ?variation_type\nFROM <http://rdfportal.org/dataset/clinvar>\nWHERE {\n  ?variant a cvo:VariationArchiveType ;\n           rdfs:label ?label ;\n           cvo:accession ?accession ;\n           cvo:number_of_submitters ?num_submitters ;\n           cvo:variation_type ?variation_type ;\n           cvo:record_status \""current\"" .\n}\nORDER BY DESC(?num_submitters)\nLIMIT 1""}}]",CRITICAL,80 submitters for GJB2 c.35del (VCV000017004),"COMPLEX QUERY requiring evidence ranking knowledge.

Databases/Resources: ClinVar

Knowledge Required:
- number_of_submitters property for evidence strength
- ORDER BY DESC for ranking
- Clinical significance path
- record_status filter

Without proper knowledge: Cannot rank variants by evidence strength.

Verified in clinvar_exploration.md Pattern 3."
84,2026-01-31,Precision,What is the development phase of Osimertinib in ChEMBL?,True,False,False,0.3333333333333333,"I don't have access to real-time ChEMBL database information in my training data that would allow me to give you the current development phase of Osimertinib with certainty.

However, I can tell you that Osimertinib (also known as Tagrisso, AZD9291) is a third-generation EGFR tyrosine kinase inhibitor that has been **approved** by regulatory agencies including the FDA and EMA for the treatment of non-small cell lung cancer (NSCLC) with specific EGFR mutations, including the T790M resistance mutation.

To get the exact development phase classification as it appears in ChEMBL, you would need to query the ChEMBL database directly, as the database is regularly updated and contains specific classification schemes for drug development phases.",,5.350808143615723,56,185,True,False,0.3333333333333333,"Perfect! I found the information about Osimertinib's development phase in ChEMBL.

## Answer

**Osimertinib (ChEMBL ID: CHEMBL3353410) has a development phase of 4 in ChEMBL.**

In ChEMBL's classification system, development phase 4 indicates that **Osimertinib is an approved/marketed drug**. This aligns with reality, as Osimertinib (marketed as Tagrisso) is an FDA-approved medication used for treating non-small cell lung cancer (NSCLC) with specific EGFR mutations.

The development phase scale in ChEMBL typically ranges from:
- Phase 0-3: Clinical trial phases
- **Phase 4: Approved/marketed drug**",,28.792582750320435,21,665,12432,117674,"mcp__togomcp__search_chembl_molecule, mcp__togomcp__get_MIE_file, mcp__togomcp__run_sparql","[{""name"": ""mcp__togomcp__search_chembl_molecule"", ""input"": {""query"": ""Osimertinib"", ""limit"": 5}}, {""name"": ""mcp__togomcp__get_MIE_file"", ""input"": {""dbname"": ""chembl""}}, {""name"": ""mcp__togomcp__run_sparql"", ""input"": {""dbname"": ""chembl"", ""sparql_query"": ""PREFIX cco: <http://rdf.ebi.ac.uk/terms/chembl#>\n\nSELECT ?molecule ?label ?chemblId ?developmentPhase\nFROM <http://rdf.ebi.ac.uk/dataset/chembl>\nWHERE {\n  ?molecule a cco:SmallMolecule ;\n            rdfs:label ?label ;\n            cco:chemblId ?chemblId ;\n            cco:highestDevelopmentPhase ?developmentPhase .\n  FILTER(?chemblId = \""CHEMBL3353410\"")\n}\nLIMIT 10""}}]",CRITICAL,Phase 4 (marketed/approved drug),"SIMPLE QUERY - Straightforward drug property lookup.

Method: search_chembl_molecule('osimertinib') then check development phase

Demonstrates when basic drug lookup tools suffice.

Verified in chembl_exploration.md simple queries section."
